Common genetic variants identify therapeutic targets for COVID-19 and

individuals at high risk of severe disease

J. E. Horowitz[1†], J. A. Kosmicki[1†], A. Damask[1], D. Sharma[1], G. H. L. Roberts[2], A. E. Justice[3], N.

Banerjee[1], M. V. Coignet[2], A. Yadav[1], J. B. Leader[3], A. Marcketta[1], D. S. Park[2], R. Lanche[1], E.

Maxwell[1], S. C. Knight[2], X. Bai[1], H. Guturu[2], D. Sun[1], A. Baltzell[2], F. S. P. Kury[1], J. D. Backman[1],

A. R. Girshick[2], C. O'Dushlaine[1], S. R. McCurdy[2], R. Partha[2], A. J. Mansfield[1], D. A. Turissini[2],

A. H. Li[1], M. Zhang[2], J. Mbatchou[1], K. Watanabe[1], L. Gurski[1], S. E. McCarthy[1], A. Verma[4], G.

Sirugo[4], Regeneron Genetics Center*, M. D. Ritchie[4], M. Jones[1], S. Balasubramanian[1], W. J.

Salerno[1], A. R. Shuldiner[1], D. J. Rader[4], T. Mirshahi[3], A. E. Locke[1], J. Marchini[1], J. D. Overton[1],

D. J. Carey[3], L. Habegger[1], M. N. Cantor[1], K. A. Rand[2], E. L. Hong[2], J. G. Reid[1], C. A. Ball[2], A.

Baras[1‡], G. R. Abecasis[1‡], M. A. Ferreira[1‡]

From:

[1]Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA

[2]AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043, USA

[3]Geisinger, Danville, PA, 17822, USA

[4]Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia,

PA, 19104, USA

*A complete list of investigators is provided in the Supplementary Appendix.

†J. A. Kosmicki and J. E. Horowitz contributed equally to this manuscript.

‡A. Baras, G. R. Abecasis and M. A. Ferreira jointly supervised this work.

Correspondence to: manuel.ferreira@regeneron.com and goncalo.abecasis@regeneron.com

ABSTRACT

The need to identify and effectively treat COVID-19 cases at highest risk for severe disease is critical. We identified seven common genetic variants (three novel) that modulate COVID-19 susceptibility and severity, implicating *IFNAR2, CCHCR1*, *TCF19*, *SLC6A20* and the hyaluronan pathway as potential therapeutic targets. A high genetic burden was strongly associated with increased risk of hospitalization and severe disease among COVID-19 cases, especially among individuals with few known risk factors.

MAIN TEXT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1] causes coronavirus disease 2019 (COVID-19)[2], which has lead to >1.5 million recorded deaths worldwide since December 2019 [3]. Reported risk factors for severe COVID-19, defined here as death or hospitalization combined with respiratory failure [4], include male sex, older age, race, obesity, kidney, cardiovascular and respiratory diseases [5-8]. Corticosteroids, repurposed anti-viral medicines, and antibody therapies have been authorized to treat COVID-19 [9-12]. Presently, excess mortality due to COVID-19 is high and the urgent need for therapies that treat or prevent severe disease remains. Further, identifying individuals at highest risk of adverse outcomes may help prioritize individuals for vaccines [13, 14] or monoclonal antibody treatments[15, 16], which are currently in short supply. In this study, we used human genetics to identify potential therapeutic targets for severe COVID-19 and developed genetic risk scores to identify individuals at highest risk of severe disease with greater precision than can be attained with clinical and demographic variables alone.

We performed genetic association studies of COVID-19 outcomes across 11,356 individuals with COVID-19 and 651,047 individuals with no record of SARS-CoV-2 infection aggregated from four studies (**Supplementary Table 1**) and four ancestries (Admixed American, African, European and South Asian). Of the COVID-19 cases, 2,175 (19%) were hospitalized and 847 (7%) had severe disease; hospitalized patients were more likely to be older, of non-European ancestry and to have pre-existing cardiovascular and lung disease (**Supplementary Table 2)**. Using these data, we defined two groups of COVID-19 outcomes: five phenotypes related to disease risk and two phenotypes related to disease severity among COVID-19 cases (**Supplementary Table 3).** For each phenotype, when >30 cases were available, we performed ancestry-specific genetic

analyses in each study (**Supplementary Table 4)** and then combined results across studies and

ancestries using a fixed-effects meta-analysis.

To identify genetic variants that modulate disease severity following SARS-CoV-2 infection, we

first focused on replicating eight independent associations ($r^2<0.05$) with disease risk reported in

recent GWAS that included >1,000 cases [17-20] (**Supplementary Table 5**); we hypothesized

that some of these published risk variants could also modulate disease severity. After accounting

for multiple testing, six variants had a significant ($P<0.0012$) and directionally consistent

association with at least one of our five disease risk phenotypes (**Supplementary Table 6**):

rs73064425 in *LZTFL1* (strongest in contrast between COVID-19 hospitalized cases vs. COVID-

19 negative or unknown controls; MAF=7%, OR=1.42, $P=7\times10^{-11}$); rs2531743 near *SLC6A20*

(COVID-19 positive vs. COVID-19 negative; MAF=42%, OR=1.06, $P=9\times10^{-4}$); rs143334143 in

the MHC (COVID-19 severe vs. COVID-19 negative or unknown; MAF=7%, OR=1.36, $P=6\times10^{-4}$

^{4}); rs9411378 in *ABO* (COVID-19 positive vs. COVID-19 negative or unknown; MAF=23%,

OR=1.12, $P=6\times10^{-10}$); rs2109069 in *DPP9* (COVID-19 positive vs. COVID-19 negative or

unknown; MAF=31%, OR=1.06, $P=10^{-4}$); and rs2236757 in *IFNAR2* (COVID-19 hospitalized vs.

COVID-19 negative or unknown; MAF=29%, OR=1.13, $P=2\times10^{-4}$). Effect sizes were comparable

across ancestries (**Supplementary Table 7**). Having established these variants as *bona fide* risk

factors for COVID-19, we then asked which (if any) were also associated with severity amongst

COVID-19 cases. We found that four of the six variants were significantly ($P<0.05$) associated

with worse outcomes among infected individuals **(Figure 1A)**. The exceptions were rs9411378 in

ABO and rs2531743 near *SLC6A20*, which did not associate with COVID-19 severity (**Figure 1B**).

Collectively, these results pinpoint four variants associated with worse disease outcomes,

including respiratory failure and death. These variants can be used to identify individuals at risk

of severe COVID-19 and suggest that nearby genes may represent targets for therapeutic

intervention.

We next looked for novel genetic associations with severe COVID-19. Across our two severity

phenotypes (hospitalized vs. non-hospitalized cases; severe vs. non-hospitalized cases), we found

no new associations at $P<5 \times 10^{-8}$ (**Supplementary Figure 1**), indicating that these analyses were

underpowered for genome-wide discovery. To increase power, we combined results from our

COVID-19 hospitalization phenotype (2,175 cases vs. 651,047 controls) with those from two

published GWAS[19, 21], for a combined sample size of 5,461 hospitalized cases and 661,632

controls with no record of SARS-CoV-2 infection. In this larger analysis of disease risk, seven loci

reached genome-wide significance (**Figure 2**), including the four highlighted by the replication

analysis above (*LZTFL1*, MHC, *DPP9* and *IFNAR2*) and three novel associations (**Table 1**):

rs79833209 near *CCNG1* (5q34; MAF=2%, OR=1.54, $P=2 \times 10^{-8}$); rs4782327 in *ACSF3* (16q24.3;

MAF=22%, OR=1.17, $P=8 \times 10^{-9}$); and rs12461764 in *FPR1* (19q13.41; MAF=35%, OR=1.18,

$P=10^{-8}$). Consistent associations were observed across studies and ancestries for the three novel

variants (**Supplementary Figure 2**). We then assessed the association between each novel variant

and disease severity and found that for all three, the risk allele was overrepresented ($P<0.05$)

amongst hospitalized and severe COVID-19 cases, relative to non-hospitalized cases (**Figure 1C**).

To further study the association between the three variants and worse disease outcomes, we

constructed a continuous score that combined nine different measures of severity self-reported by

4,448 COVID-19 cases from the AncestryDNA study. Lower severity scores were enriched for

asymptomatic cases and lower symptom severity, while higher scores were associated with

increased symptom severity and elevated hospitalization rates (**Supplementary Figure 3**). The

mean severity score was elevated for carriers of each of the three novel risk alleles

(**Supplementary Table 8**). Therefore, the three putative novel susceptibility loci we identified for

COVID-19 risk are also associated with increased risk of severe disease.

Collectively, our association analyses highlighted seven common variants (four known, three

novel) associated with COVID-19 susceptibility ($P<5\text{x}10^{-8}$), as well as disease severity among

cases ($P<0.05$). As all seven variants are either intronic or intergenic, it is not immediately clear

how these variants influence gene function. To help identify gene targets and thus potential

therapeutic targets for severe COVID-19, we searched for functional protein-coding variants

(missense or predicted loss-of-function) in high LD ($r^2>0.95$) with each variant. We found six

functional variants in three genes: two missense variants in *IFNAR2*, a component of the

heterodimeric type-1 interferon receptor; three missense and a stop-gain variant in *CCHCR1*, a P-

body protein associated with cytoskeletal remodeling and mRNA turnover [22, 23], which can

interact with human papillomavirus-16 [24, 25]; and a missense variant in *TCF19*, a transcription

factor associated with hepatitis B [26, 27] (**Supplementary Table 9**). These data indicate that the

risk variants identified in *IFNAR2*, *CCHCR1* and *TCF19* may have functional effects on these

genes. Next, we asked if the sentinel risk variants co-localized *($r^2>0.95$)* with published sentinel

expression quantitative trait loci (**Supplementary Table 10**), specifically focusing on 168 genes

in *cis* (± 500 kb). We observed evidence for co-localization for *IFNAR2, TCF19* and *SLC6A20*

(**Supplementary Table 11**). *SLC6A20* encodes a proline transporter that binds the host SARS-

CoV-2 receptor, angiotensin-converting enzyme 2 [28]. Our results suggest that higher *SLC6A20*

expression in the lung (and potentially increased viral uptake) is associated with higher risk of

severe disease (**Supplementary Table 11**). In contrast, for *IFNAR2*, our analysis suggests that

severe COVID-19 is associated with lower expression in immune cells and lung tissue

(**Supplementary Table 11**), consistent with the deficient interferon response observed in severe

COVID-19 patients [29]. Collectively, these analyses identified four specific putative effector

genes in COVID-19 risk loci *(IFNAR2, CCHCR1, TCF19* and *SLC6A20)*, though functional

studies are required to confirm these predictions.

Co-localization analyses did not identify any likely target genes for the three new risk variants.

However, we note that two of these (rs12461764 and rs79833209) are near genes related to

hyaluronan (HA), a major component of the lung extracellular matrix (**Supplementary Figure 2**):

HAS1 (16 Kb away) and *HMMR* (160 Kb away), which respectively encode HA synthase 1 and a

cell-surface receptor for HA. This observation is noteworthy because elevated HA (i) has been

reported in the lungs of COVID-19 patients [30, 31]; and (ii) is associated with inflammation and

other infections [31], including influenza [33]. Furthermore, *Hmmr*-deficient mice are protected

in acute fibrotic lung injury models [34]. If confirmed, these findings would support the use of

hyaluronidases in reducing accumulation of HA and preventing long-term lung damage in

COVID-19 patients [35].

The second aim of this study was to determine if genetics can help identify individuals at high risk

of severe disease, who may be prioritized for prophylactic or therapeutic interventions.

Specifically, we focused on the four variants (in/near *LZTFL1*, MHC, *DPP9* and *IFNAR2*) with

confirmed association with COVID-19 susceptibility and that also modulate COVID-19 severity.

Using these variants, we created a weighted genetic risk score (GRS) for individuals with COVID-

19 and then compared the risk of hospitalization and severe disease between those with a high

GRS and all other cases, after adjusting for established risk factors (*e.g.* age, sex, comorbidities).

When considering COVID-19 cases of European ancestry (N=9,277), we found that having a high

GRS (top 10%) was associated with a 2.0-fold increased risk of hospitalization (95% CI 1.66-2.55,

P=3x10^{-11}; **Supplementary Figure 4A**) and 1.8-fold increased risk of severe disease (95% CI

1.40-2.41, P=10^{-5}; **Figure 3A**). A consistent pattern was observed in other ancestries, though

sample sizes were considerably smaller (**Supplementary Tables 12** and **13**). Lastly, we compared

the effect of the GRS between individuals with and without established risk factors for severe

COVID-19. We found that a high GRS (top 10%) was strongly associated with risk of severe

disease among individuals with one (OR=3.26, 95% CI 2.03-5.23, P=10^{-6}) or two (OR=2.19, 95%

CI 1.29-3.72, P=0.004) established risk factors (**Figure 3B** and **3C; Supplementary Table 14**).

In contrast, there was a much weaker association between a high GRS and risk of severe disease

among individuals with many (three or more) risk factors (OR=1.26, 95% CI 0.75-2.11, P=0.388),

although evidence for heterogeneity of GRS effect with number of risk factors was not significant

(P=0.16). Similar results were observed for risk of hospitalization (**Supplementary Figure 4B**

and **4C; Supplementary Table 14**). Collectively, these results demonstrate that a GRS calculated

using variants associated with disease risk and severity can be used to identify COVID-19 cases

at high risk of developing poor disease outcomes. This is important as many of these individuals

might not be prioritized for prophylactic or therapeutic interventions according to current

guidelines[35].

In summary, we confirmed four common variant associations with COVID-19 susceptibility and

further show that they modulate disease severity and are likely to influence the function of

IFNAR2, *CCHCR1*, *TCF19* and *SLC6A20*. We also identified three novel associations with disease

severity, which potentially provide genetic evidence for a role of hyaluronan in severe COVID-

19. Lastly, we show that a genetic risk score based on the four common variants that we validated

can be used to identify individuals at high risk of poor disease outcomes. Collectively, our analyses

point to potential novel therapies and help identify patients at high risk of severe COVID-19.

ONLINE METHODS

Participating Studies

AncestryDNA COVID-19 Research Study. AncestryDNA customers over age 18, living in the United States, and who had consented to research, were invited to complete a survey assessing COVID-19 outcomes and other demographic information. These included SARS-CoV-2 swab and antibody test results, COVID-19 symptoms and severity, brief medical history, household and occupational exposure to SARS-CoV-2, and blood type. A total of 83,930 AncestryDNA survey respondents were selected for inclusion in this study [36, 37]. Respondents selected for this study included all individuals with a positive COVID-19 test together with age and sex matched controls. DNA samples were genotyped as described previously[36]. Genotype data for variants not included in the array were then inferred using imputation to the Haplotype Reference Consortium (HRC) reference panel. Briefly, samples were imputed to HRC version 1.1, which consists of 27,165 total individuals and 36 million variants. The HRC reference panel does not include indels; consequently, indels are not present in the imputed data. We determined best-guess haplotypes with Eagle version 2.4.1 and performed imputation with Minimac4 version 1.0.1. We used 1,117,080 unique variants as input and 8,049,082 imputed variants were retained in the final data set. Variants with a Minimac4 $R^2 < 0.30$ were filtered from the analysis. For this study, an additional continuous severity phenotype was defined for a semi-overlapping set of in 4,448 survey-respondents that reported a positive COVID-19 test. The continuous severity score was derived by computing the first principal component across nine survey fields related to COVID-19 clinical outcomes. Six of the nine questions were binary: hospitalization, ICU admittance with oxygen, ICU admittance with ventilation, septic shock, respiratory failure, and organ failure due to COVID-19. Binary responses were encoded as 0 for "No" and 1 for "Yes". Three symptom

questions related to shortness of breath, fever, and nausea/vomiting symptoms were encoded as a

unit-scaled variable based on the following mapping: 0="None", 0.2="Very mild", 0.4="Mild",

0.6="Moderate", 0.8="Severe", and 1.0="Very Severe". The three symptoms were chosen based

on prior literature indicating their positive association with COVID-19 hospitalization[37]. The

resulting score was standardized prior to association analysis.

Geisinger Health System (GHS). The GHS MyCode Community Health Initiative is a health

system-based cohort from central and eastern Pennsylvania (USA) with ongoing recruitment since

2006. A subset of 144,182 MyCode participants sequenced as part of the GHS-Regeneron Genetics

Center DiscovEHR partnership were included in this study. Information on COVID-19 outcomes

were obtained through GHS's COVID-19 registry. Patients were identified as eligible for the

registry based on relevant lab results and ICD-10 diagnosis codes; patient charts were then

reviewed to confirm COVID-19 diagnoses. The registry contains data on outcomes, comorbidities,

medications, supplemental oxygen use, and ICU admissions. DNA from participants was

genotyped on either the Illumina OmniExpress Exome (OMNI) or Global Screening Array (GSA)

and imputed to the TOPMed reference panel (stratified by array) using the TOPMed Imputation

Server. Prior to imputation, we retained variants that had a MAF >= 0.1%, missingness < 1% and

HWE p-value > 10^{-15}. Following imputation, data from the OMNI and GSA datasets were merged

for subsequent association analyses, which included an OMNI/GSA batch covariate, in addition

to other covariates described below.

Penn Medicine BioBank (PMBB) study. PMBB study participants are recruited through the
University of Pennsylvania Health System, which enrolls participants during hospital or clinic
visits. Participants donate blood or tissue and allow access to EHR information[38]. The PMBB
COVID-19 registry consists of patients who have positive qPCR testing for SARS-COV-2. We
then used electronic health records to classify COVID-19 patients into hospitalized and severe
(ventilation or death) categories. DNA genotyping was performed with the Illumina Global
Screening Array, and imputation performed using the TOPMed reference panel as described for
GHS above.

UK Biobank (UKB) study. We studied the host genetics of SARS-CoV-2 infection in participants
of the UK Biobank study, which took place between 2006 and 2010 and includes approximately
500,000 adults aged 40-69 at recruitment. In collaboration with UK health authorities, the UK
Biobank has made available regular updates on COVID-19 status for all participants, including
results from four main data types: qPCR test for SARS-CoV-2, anonymized electronic health
records, primary care and death registry data. We report results based on the 12 September 2020
data refresh and excluded from the analysis 28,547 individuals with a death registry event prior to
2020. DNA samples were genotyped as described previously [39] using the Applied Biosystems
UK BiLEVE Axiom Array (N=49,950) or the closely related Applied Biosystems UK Biobank
Axiom Array (N=438,427). Genotype data for variants not included in the arrays were inferred
using three reference panels (Haplotype Reference Consortium, UK10K and 1000 Genomes
Project phase 3) as described previously [39].

COVID-19 phenotypes used for genetic association analyses

We grouped participants from each study into three broad COVID-19 disease categories

(**Supplementary Table 1**): (i) positive – those with a positive qPCR or serology test for SARS-

CoV-2, or a COVID-19-related ICD10 code (U07), hospitalization or death; (ii) negative – those

with only negative qPCR or serology test results for SARS-CoV-2 and no COVID-19-related

ICD10 code (U07), hospitalization or death; and (iii) unknown – those with no qPCR or serology

test results and no COVID-19-related ICD10 code (U07), hospitalization or death. We then used

these broad COVID-19 disease categories, in addition to hospitalization and disease severity

information, to create seven COVID-19-related phenotypes for genetic association analyses, as

detailed in **Supplementary Table 3**. For association analysis in the AncestryDNA study, we

excluded from the COVID-19 unknown group individuals who had (i) a first-degree relative who

was COVID-19 positive; or (ii) flu-like symptoms.

Genetic association analyses

Association analyses in each study were performed using the genomewide Firth logistic regression

test implemented in REGENIE [40]. In this implementation, Firth's approach is applied when the

p-value from standard logistic regression score test is below 0.05. We included in step 1 of

REGENIE (*i.e.* prediction of individual trait values based on the genetic data) directly genotyped

variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-Weinberg

equilibrium test P-value>10^{-15} and linkage-disequilibrium (LD) pruning (1000 variant windows,

100 variant sliding windows and r^2<0.9). The association model used in step 2 of REGENIE

included as covariates age, age^2, sex, age-by-sex, and the first 10 ancestry-informative principal

components (PCs) derived from the analysis of a stricter set of LD-pruned (50 variant windows, 5

variant sliding windows and $r^2<0.5$) common variants from the array (imputed for the GHS study)

data.

Within each study, association analyses were performed separately for four different ancestries

defined based on the array data (African [AFR], admixed American [AMR], European [EUR] and

South Asian [SAS]). We retained association results for variants with an imputation information

score $\geq$0.3 and MAC $\geq$5, and either (i) MAF>0.5% or (ii) a protein-altering consequence (*i.e.*

pLOF, missense or splice variants). Results were subsequently meta-analyzed across studies and

ancestries using an inverse variance-weighed fixed-effects meta-analysis.

Identification of putative targets of GWAS variants based on colocalization with eQTL

We identified as a likely target of a sentinel GWAS variant any gene for which a sentinel

expression quantitative trait locus (eQTL) co-localized (*i.e.* had LD $r^2 > 0.95$) with the sentinel

GWAS variant. That is, we only considered genes for which there was strong LD between a

sentinel GWAS variant and a sentinel eQTL, which reduces the chance of spurious colocalization.

Sentinel eQTL were defined across 174 published datasets (**Supplementary Table 10**), as

described previously[41]. We did not use statistical approaches developed to distinguish

colocalization from shared genetic effects because these have very limited resolution at high LD

levels ($r^2 > 0.8$)[42].

Genetic risk score (GRS) analysis of COVID-19 hospitalization and severity

First, in each study (AncestryDNA, GHS, UKB and PMBB), we created a GRS for each COVID-

19 positive individual based on variants that were reported to associate with COVID-19

susceptibility in previous GWAS and that we (i) independently replicated; and (ii) found to be

associated with COVID-19 severity. We used as weights the effect (beta) reported in previous

GWAS (**Supplementary Table 5**). Second, we ranked COVID-19 individuals based on the GRS

and created a new binary GRS predictor by assigning each individual to a high (top 5%) or low

(rest of the population) percentile group. Third, for studies with >100 hospitalized cases, the we

used logistic regression to test the association between the binary GRS predictor and risk of

hospitalization (hospitalized cases vs. all other cases), including as covariates age, sex and ten

ancestry-informative PCs. In addition to age and sex, we included as additional covariates

established clinical risk factors for COVID-19 that were significantly associated in each respective

study: BMI, smoking status, hypertension and chronic kidney disease for GHS; BMI, smoking

status, hypertension and chronic obstructive pulmonary disease in Europeans of the UKB;

hypertension, CKD, COPD, diabetes in AncestryDNA. We repeated the association analysis (i)

using different percentile cut-offs for the GRS (5%, 10%, 20%, 30% and 40%); and (ii) to test the

association with disease severity (severe cases vs. all other cases).

<u>Results availability</u>

All genotype-phenotype association results reported in this study are available for browsing using

the RGC's COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use

is limited to research purposes in accordance with the Terms of Use (https://rgc-

covid19.regeneron.com/terms-of-use).

<u>Competing interests</u>

J.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., H.G., D.S., F.S.P.K., J.D.B., C.O.,
A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, M.J., S.B., W.J.S., A.R.S., A.E.L., J.M., J.O.,
L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of
Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R., M.V.C., D.S.P., S.C.K.
A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current employees at
AncestryDNA and may hold equity in AncestryDNA. The other authors declare no competing
interests.
320

321 **FIGURES**

Figure 1. Comparison of effect sizes across COVID-19 susceptibility and severity outcomes for six previously reported (A) and three novel (B) risk variants.

Figure 1. Comparison of effect sizes across COVID-19 susceptibility and severity outcomes

for six previously reported (A, B) and three novel (C) risk variants.

(A, B) Six variants that were reported to associated with COVID-19 susceptibility in previous

studies and replicated in our analysis. Of these, four variants also associated with disease severity

among COVID-19 cases (in/near *LZTFL1*, *CCHCR1*, *DPP9* and *IFNAR2*; panel A), whereas two

variants did not (in *ABO* and *SLC6A20*, panel B).

(C) Three novel risk variants for COVID-19 discovered in the trans-ancestry meta-analysis of risk

of COVID-19 hospitalization across six studies (AncestryDNA, GHS, UKB, PMBB,

Ellinghaus[19] et al. and Pairo-Castineira et al.[18]).

Figure 2. Summary of association results from the trans-ancestry meta-analysis of risk of

COVID-19 hospitalization. The meta-analysis included results from six studies (AncestryDNA,

GHS, UKB, PMBB, Ellinghaus et al. [19] and Pairo-Castineira et al.[18] and four ancestries (AFR,

AMR, EUR and SAS), totaling 5,461 hospitalized cases and 661,632 controls with no record of

SARS-CoV-2 infection.

Figure 3. Association between a four-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases of European ancestry.

(A) Association between high genetic risk and severe disease. Overall risk of severe disease is shown for individuals in the top GRS percentile, agnostic to the number of clinical risk factors present. The association was tested in two studies separately (AncestryDNA and UKB studies) using logistic regression, with established risk factors for COVID-19 included as covariates (see Methods for details). Results were then meta-analyzed across studies, for a combined sample size of 8,423 COVID-19 cases, including 744 with severe disease. N in red: number of COVID-19 cases in the top GRS percentile. N in grey: number of COVID-19 cases in the rest of population.

(B) Rate of severe disease in UK Biobank and AncestryDNA study, after stratifying by the number of clinical risk factors and genetic risk score. High genetic risk: top 10% of the GRS. Low genetic risk: bottom 90% of the GRS (*i.e.* all other COVID-19 cases).

(C) Association between high genetic risk (top 10% of GRS vs. all other COVID-19 cases) and

severe disease, after stratifying by the number of pre-existing clinical risk factors. The association

was tested in the UK Biobank and AncestryDNA studies, with results combined using inverse-

variance meta-analysis.

TABLES

Table 1. Top associations identified in the trans-ancestry meta-analysis of risk of COVID-19

hospitalization. The meta-analysis included results from six studies (AncestryDNA, GHS, UKB,

PMBB, Pairo-Castineira et al.[18] and Ellinghaus et al. [19]) and four ancestries (AFR, AMR,

EUR and SAS), totaling 5,461 hospitalized cases and 661,632 controls with no record of SARS-

CoV-2 infection.

rsID	Position hg38	Effect allele	Odds ratio (LCI,UCI)	P-value	Effect allele frequency	N cases (N with 0|1|2 copies of the effect allele)	N controls (N with 0|1|2 copies of the effect allele)	Nearest gene
Previously reported associations								
rs73064425	3:45859597	T	1.716 (1.589, 1.854)	5.42E-43	0.074	5461 (4205|1165|87)	661632 (568579|88970|4081)	*LZTFL1*
rs143334143	6:31153649	A	1.335 (1.233, 1.447)	1.29E-12	0.072	5461 (4525|881|52)	661632 (569685|88265|3678)	*CCHCR1*
rs2277732	19:4723658	A	1.225 (1.166, 1.287)	8.40E-16	0.300	5461 (2371|2411|677)	661632 (325425|276058|60146)	*DPP9*
rs13050728	21:33242905	T	1.210 (1.153, 1.270)	1.24E-14	0.315	5461 (2237|2491|729)	661632 (311728|283741|66160)	*IFNAR2*
Novel associations								
rs79833209	5:163300447	T	1.544 (1.326, 1.796)	2.02E-08	0.022	5387 (5072|308|4)	652327 (624117|27910|296)	*CCNG1*
rs4782327	16:89117727	G	1.171 (1.110, 1.236)	8.15E-09	0.216	5461 (3109|2002|346)	661632 (407670|222489|31470)	*ACSF3*
rs12461764	19:51739497	G	1.181 (1.116, 1.250)	1.11E-08	0.346	3785 (1431|1770|582)	653252 (279857|295218|78176)	*FPR1*

366
367

 SUPPLEMENTARY FIGURES

Provided in a separate file.

Supplementary Figure 1. Summary of association results from the meta-analysis of two

phenotypes related to disease severity among COVID-19 cases. **(A)** Phenotype COVID-19

positive hospitalized (N=2,052) vs COVID-19 positive and not hospitalized (N=9,098). **(B)**

Phenotype COVID-19 positive severe (N=815) vs COVID-19 positive and not hospitalized

(N=8,999).

Supplementary Figure 2. Three novel loci identified in the trans-ancestry meta-analysis of

risk of COVID-19 hospitalization. (A) rs79833209 (5:163300447:C:T, effect allele C) in 5q34,

near *CCNG1*. **(B)** rs4782327 (16:89117727:G:C, effect allele G) in 16q24.3 in *ACSF3*. **(C)**

rs12461764 (19:51739497:G:T, effect allele G) in 19q13.41 near *FPR1*. RR: number of individuals

homozygous for reference allele. RA: number of heterozygous individuals. RA: number of

individuals homozygous for alternative (effect) allele. AAF: alternative allele frequency. OR: odds

ratio.

Supplementary Figure 3. Association between the continuous severity score and key

individual measures of severity in the AncestryDNA study. The continuous severity score was

derived from the first principal component across nine survey fields related to COVID-19 clinical

outcomes, including three symptoms, hospitalization, ICU admittance, and other severe

complications due to COVID-19 illness (Methods). Plots reflect mean symptom severity (top three

panels) or incident prevalence (bottom three panels) for several fields as a function of ascending

severity decile. Symptom information was encoded as follows: 0=None, 0.2=Very Mild, 0.4=Mild,

0.6=Moderate, 0.8=Severe, and 1.0=Very Severe. A paucisymptomatic case corresponds to

reporting symptoms of mild intensity or less for any of the symptom severity questions.

Supplementary Figure 4. Association between a four-SNP genetic risk score (GRS) and risk

of hospitalization among COVID-19 cases of European ancestry.

(A) Association between high genetic risk and hospitalization. Overall risk of hospitalization is

shown for individuals in the top GRS percentile, agnostic to the number of clinical risk factors

present. The association was tested in three studies separately (AncestryDNA, GHS and UKB

studies) using logistic regression, with established risk factors for COVID-19 included as

covariates (see Methods for details). Results were then meta-analyzed across studies, for a

combined sample size of 9,277 COVID-19 cases, including 1,832 who were hospitalized. N in red:

number of COVID-19 cases in the top GRS percentile. N in grey: number of COVID-19 cases in

the rest of population.

(B) Rate of hospitalization in UK Biobank and AncestryDNA study, after stratifying by the number

of clinical risk factors and genetic risk score. High genetic risk: top 10% of the GRS. Low genetic

risk: bottom 90% of the GRS (*i.e.* all other COVID-19 cases).

(C) Association between high genetic risk (top 10% of GRS vs. all other COVID-19 cases) and

hospitalization, after stratifying by the number of pre-existing clinical risk factors. The association

was tested in the UK Biobank and AncestryDNA studies, with results combined using inverse-

variance meta-analysis.

SUPPLEMENTARY TABLES

Provided in a separate file.

Supplementary Table 1. Breakdown of COVID-19 status across the four studies included in the analysis.

Supplementary Table 2. Demographics and clinical characteristics of study participants.

Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed.

Supplementary Table 4. Genomic inflation factor (lambda) across the seven COVID-19 phenotypes analyzed.

Supplementary Table 5. Eight variants associated with COVID-19 susceptibility in previous GWAS.

Supplementary Table 6. Association between eight published risk variants for COVID-19 and five disease susceptibility phenotypes in this study. P-values shown in red were significant after correcting for the 40 tests performed ($P<0.00125$).

Supplementary Table 7. Comparison of effect sizes between ancestries for the six published risk variants that were validated in this study.

Supplementary Table 8. Association between a COVID-19 severity score and seven variants (four known, three novel) associated with both disease risk and severity.

Supplementary Table 9. Missense or predicted loss-of-function variants in high linkage disequilibrium (LD, r^2>0.95) with sentinel GWAS variants.

Supplementary Table 10. Published gene expression datasets used to identify sentinel expression quantitative trait loci (eQTL) that co-localized (LD r^2>0.95) with sentinel GWAS variants.

Supplementary Table 11. Expression quantitative trait loci (eQTL) that co-localized (LD r^2>0.95) with sentinel GWAS variants.

Supplementary Table 12. Association between a four-SNP genetic risk score (GRS) and risk of hospitalization among COVID-19 cases.

Supplementary Table 13. Association between a four-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases.

Supplementary Table 14. Association between a four-SNP genetic risk score (GRS) and risk of hospitalization and severe disease, after stratifying COVID-19 cases by the number of pre-existing clinical risk factors for severe COVID-19.

References

1.   Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019.* New

England Journal of Medicine, 2020. **382**(8): p. 727-733.

2.   Coronaviridae Study Group of the International Committee on Taxonomy of, V., *The*

species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV

and naming it SARS-CoV-2. Nat Microbiol, 2020. **5**(4): p. 536-544.

3.   *World Health Organization Coronavirus Disease Weekly Epidemiological Update.* 2020;

Available from: https://covid19.who.int/.

4.   Guan, W.J., et al., *Clinical Characteristics of Coronavirus Disease 2019 in China.* N

Engl J Med, 2020. **382**(18): p. 1708-1720.

5.   Richardson, S., et al., *Presenting Characteristics, Comorbidities, and Outcomes Among*

5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama, 2020.

323(20): p. 2052-2059.

6.   Atkins, J.L., et al., *PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-*

19 IN OLDER ADULTS IN THE UK BIOBANK COMMUNITY COHORT. medRxiv,

2020: p. 2020.05.06.20092700.

7.   Zhou, F., et al., *Clinical course and risk factors for mortality of adult inpatients with*

COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020. **395**(10229): p.

1054-1062.

8.   Cummings, M.J., et al., *Epidemiology, clinical course, and outcomes of critically ill*

adults with COVID-19 in New York City: a prospective cohort study. Lancet, 2020.

395(10239): p. 1763-1770.

9.   Rochwerg, B., *A living WHO guideline on drugs for covid-19.* BMJ 2020;370:m3379

482   2020.

483   10.   Group, R.C., et al., *Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary*

484   *Report.* N Engl J Med, 2020.

485   11.   FDA, *Investigational COVID-19 Convalescent Plasma.* 2020.

486   12.   *WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 –interim*

487   *WHO SOLIDARITY trial results*. medRxiv 2020; Available from:

488   https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1?ijkey=6ff7378035b5

489   c9c24346a6b90cadb5e866a63f71&keytype2=tf_ipsecsha.

490   13.   Jackson, L.A., et al., *An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.* N

491   Engl J Med, 2020. **383**(20): p. 1920-1931.

492   14.   Walsh, E.E., et al., *Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine*

493   *Candidates.* N Engl J Med, 2020.

494   15.   Hansen, J., et al., *Studies in humanized mice and convalescent humans yield a SARS-*

495   *CoV-2 antibody cocktail.* Science, 2020. **369**(6506): p. 1010-1014.

496   16.   Baum, A., et al., *Antibody cocktail to SARS-CoV-2 spike protein prevents rapid*

497   *mutational escape seen with individual antibodies.* Science, 2020. **369**(6506): p. 1014-

498   1018.

499   17.   Shelton, J., F., Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa Filshtein-

500   Somnez, Daniella Coker, Antony Symons, Jorge Esparza-Gordillo, The 23andMe

501   COVID-19 Team, Stella Aslibekyan, Adam Auton, *Trans-ethnic analysis reveals genetic*

502   *and non-genetic associations with COVID-19 susceptibility and severity.* 2020.

503   18.   Pairo-Castineira, E., et al, … The GenOMICC Investigators, The ISARIC4C

504   Investigators, The Covid-19 Human Genetics Initiative, Xia Shen, Kathy Rowan, Angie

505   Fawkes, Lee Murphy, Chris P Ponting, Albert Tenesa, Mark Caulfield, Richard

506   Scott, Peter JM Openshaw, Malcolm G Semple, Veronique Vitart, James F Wilson,

507   J Kenneth Baillie, *Genetic mechanisms of critical illness in Covid-19.* medRxiv, 2020: p.

508   2020.09.24.20200048.

509   19.   Ellinghaus, D., et al., *Genomewide Association Study of Severe Covid-19 with*

510   *Respiratory Failure.* New England Journal of Medicine, 2020.

511   20.   *The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host*

512   *genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.* Eur J

513   Hum Genet, 2020. **28**(6): p. 715-718.

514   21.   Tervaniemi, M.H., et al., *Intracellular signalling pathways and cytoskeletal functions*

515   *converge on the psoriasis candidate gene CCHCR1 expressed at P-bodies and*

516   *centrosomes.* BMC Genomics, 2018. **19**(1): p. 432.

517   22.   Ling, Y.H., et al., *CCHCR1 interacts with EDC4, suggesting its localization in P-bodies.*

518   Exp Cell Res, 2014. **327**(1): p. 12-23.

519   23.   Olejnik-Schmidt, A.K., et al., *Search for cellular partners of human papillomavirus type*

520   *16 E2 protein.* Arch Virol, 2008. **153**(5): p. 983-90.

521   24.   Muller, M. and C. Demeret, *CCHCR1 interacts specifically with the E2 protein of human*

522   *papillomavirus type 16 on a surface overlapping BRD4 binding.* PLoS One, 2014. **9**(3):

523   p. e92581.

524   25.   Matsuura, K., M. Isogawa, and Y. Tanaka, *Host genetic variants influencing the clinical*

525   *course of hepatitis B virus infection.* J Med Virol, 2016. **88**(3): p. 371-9.

26.   Kim, Y.J., et al., *A genome-wide association study identified new variants associated*
with the risk of chronic hepatitis B. Hum Mol Genet, 2013. **22**(20): p. 4233-8.

27.   Vuille-dit-Bille, R.N., et al., *Human intestine luminal ACE2 and amino acid transporter*
expression increased by ACE-inhibitors. Amino Acids, 2015. **47**(4): p. 693-705.

28.   Hadjadj, J., et al., *Impaired type I interferon activity and inflammatory responses in*
severe COVID-19 patients. Science, 2020. **369**(6504): p. 718-724.

29.   Hellman, U., et al., *Presence of hyaluronan in lung alveoli in severe Covid-19: An*
opening for new treatment options? J Biol Chem, 2020. **295**(45): p. 15418-15422.

30.   Kaber, G., et al., *Hyaluronan is abundant in COVID-19 respiratory secretions.* medRxiv,
2020.

31.   Siiskonen, H., et al., *Hyaluronan synthase 1: a mysterious enzyme with unexpected*
functions. Front Immunol, 2015. **6**: p. 43.

32.   Bell, T.J., et al., *Defective lung function following influenza virus is due to prolonged,*
reversible hyaluronan synthesis. Matrix Biol, 2019. **80**: p. 14-28.

33.   Cui, Z., et al., *The Receptor for Hyaluronan-Mediated Motility (CD168) promotes*
inflammation and fibrosis after acute lung injury. Matrix Biol, 2019. **78-79**: p. 255-271.

34.   Shi, Y., et al., *COVID-19 infection: the perspectives on immune responses.* Cell Death
Differ, 2020. **27**(5): p. 1451-1454.

35.   *How CDC Is Making COVID-19 Vaccine Recommendations*. 2020 [cited 2020
December 2, 2020]; Available from: https://www.cdc.gov/coronavirus/2019-
ncov/vaccines/recommendations-process.html.

36.   Roberts, G.H.L., *AncestryDNA COVID-19 Host Genetic Study Identifies Three Novel*
Loci. medRxiv, 2020.

37.   Knight, S.C., *COVID-19 Susceptibilityand Severity Risks in a Survey of Over 500,000*

People. medRxiv, 2020.

38.   Park, J., et al., *A genome-first approach to aggregating rare genetic variants in LMNA*

for association with electronic health record phenotypes. Genet Med, 2020. **22**(1): p.

102-111.

39.   Bycroft, C., et al., *The UK Biobank resource with deep phenotyping and genomic data.*

Nature, 2018. **562**(7726): p. 203-209.

40.   Mbatchou, J., et al., *Computationally efficient whole genome regression for quantitative*

and binary traits. bioRxiv, 2020: p. 2020.06.19.162354.

41.   Ferreira, M.A., et al., *Shared genetic origin of asthma, hay fever and eczema elucidates*

allergic disease biology. Nat Genet, 2017. **49**(12): p. 1752-1757.

42.   Chun, S., et al., *Limited statistical evidence for shared genetic effects of eQTLs and*

autoimmune-disease-associated loci in three major immune-cell types. Nat Genet, 2017.

49(4): p. 600-605.

MAIN FIGURES

Figure 1. Comparison of effect sizes across COVID-19 susceptibility and severity outcomes for six previously reported (A, B) and three novel (C) risk variants.

Figure 2. **Summary of association results from the trans-ancestry meta-analysis of risk of COVID-19 hospitalization.** The meta-analysis included results from six studies (AncestryDNA, GHS, UKB, PMBB, Ellinghaus et al. [19] and Pairo-Castineira et al. [18]) and four ancestries (AFR, AMR, EUR and SAS), totaling 5,461 hospitalized cases and 661,632 controls with no record of SARS-CoV-2 infection.

Figure 3. Association between a four-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases of European ancestry.